CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant

Rhea-AI Filing Summary

Zevra Therapeutics, Inc. reported that its CFO, Justin A. Renz, received a grant of stock options to purchase 300,000 shares of common stock. The options have an exercise price of $9.55 per share, equal to the closing market price on March 18, 2026, and expire ten years after the grant date.

The award was made under Zevra’s 2023 Employment Inducement Award Plan and vests in four equal annual installments beginning on the first anniversary of the grant, subject to continued service. All underlying shares will vest in full immediately before a change of control, and vesting will be accelerated by 12 months if the CFO is terminated without cause or resigns for good reason.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Renz Justin A

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.55(1)	03/18/2026		A		300,000		(2)	03/17/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, March 18, 2026.

2. Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of the Issuer. Vesting of the option will be accelerated by 12 months if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.

Remarks:

	/s/ Brian Keane, Attorney-in-Fact for Justin Renz	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Zevra Therapeutics (ZVRA) disclose for its CFO?

Zevra Therapeutics disclosed that CFO Justin A. Renz received a stock option grant for 300,000 shares. The options are a compensation award, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.

What are the key terms of the Zevra (ZVRA) CFO’s 300,000-share option grant?

The CFO received options on 300,000 shares with a $9.55 exercise price and a ten-year term. The options vest in four equal annual installments starting one year after the March 18, 2026 grant date, contingent on continued service with the company.

How do the Zevra (ZVRA) CFO’s stock options vest over time?

The stock options vest in four equal annual installments beginning on the first anniversary of the March 18, 2026 grant. Vesting requires the CFO to remain in service on each vesting date, aligning the award with long-term employment and company performance.

What happens to the Zevra (ZVRA) CFO’s options if there is a change of control?

All shares underlying the CFO’s stock option will vest and become exercisable immediately before a change of control. This provision ensures the award is not forfeited if the company is sold or undergoes a major ownership transition affecting control.

Are there acceleration protections for the Zevra (ZVRA) CFO if employment ends?

Yes. Vesting of the CFO’s stock option will be accelerated by 12 months if he is terminated without cause or resigns for good reason. This provides partial protection for unvested equity in certain adverse employment separation scenarios.

Is the Zevra (ZVRA) CFO’s Form 4 transaction an open-market stock purchase or sale?

No. The Form 4 reports a grant of stock options as compensation, coded as an acquisition (A), rather than an open-market purchase or sale. The CFO acquires derivative rights to buy shares later instead of trading existing shares in the market.